GE HealthCare builds on BARDA collaboration with approximately $35 million expansion to advance artificial intelligence-powered ultrasound for trauma care and emergency preparedness
GE HealthCare builds on BARDA collaboration with approximately $35 million expansion to advance artificial intelligence-powered ultrasound for trauma care and emergency preparedness
biomedical advanced research and development authorityregulatory
A biomedical advanced research and development authority is a government agency that funds and guides the late-stage development and manufacturing of drugs, vaccines, diagnostics and other health technologies, especially those needed for public health emergencies. For investors it matters because its contracts, grants or technical support act like a bridge and safety net—reducing development risk, accelerating timelines and creating a more reliable path to revenue for companies working on critical medical products.
administration for strategic preparedness and responseregulatory
A federal office that coordinates planning, stockpiles, procurement and response for national public-health emergencies like pandemics, biological threats and large-scale medical disasters. Think of it as the country’s emergency manager for medical supplies, vaccines and treatment capacity; its decisions on funding, contracts, product approvals and distribution can directly affect healthcare companies, supply chains and investor expectations about demand and regulatory timing.
artificial intelligencetechnical
Artificial intelligence is the ability of computers and machines to perform tasks that typically require human thinking, such as understanding language, recognizing patterns, or making decisions. For investors, it matters because AI can enhance efficiency, uncover new insights, and enable smarter strategies, potentially impacting the value and performance of companies that develop or utilize this technology.
mass casualty incidentsmedical
Mass casualty incidents are events that create far more injured or ill people than local medical and emergency systems can care for at once, such as large accidents, natural disasters, or acts of mass violence. For investors, they matter because they can sharply increase demand for medical supplies, emergency services, insurance payouts and infrastructure repair, disrupt business operations, and prompt sudden government spending or regulatory responses—like a traffic jam that forces resources and money to be rerouted.
point-of-care ultrasoundmedical
Point-of-care ultrasound is a portable imaging tool used by clinicians at the bedside, in clinics or in the field to produce real-time pictures of organs, blood flow or injuries—think of it as a pocket-sized camera for seeing inside the body. It matters to investors because these devices can speed diagnosis, lower costs, shift volumes away from large imaging centers, and create sales and service opportunities for medical device and software companies, affecting growth and margins.
lung pathologiesmedical
Lung pathologies are diseases or abnormal conditions affecting the lungs—such as infections, chronic diseases, tumors or scarring—that interfere with breathing and oxygen delivery. Investors care because the prevalence, severity and treatability of these conditions drive demand for diagnostics, drugs, devices and care services; like weather shaping crop yields, changes in lung-disease trends, new treatments, or regulatory approvals can materially affect the revenues and valuations of healthcare companies.
pleural pathologiesmedical
Pleural pathologies are diseases or injuries that affect the pleura, the thin membrane that wraps the lungs and lines the chest cavity, such as fluid buildup, inflammation, air leaks, scarring, or tumors. Think of the pleura as a seal around an engine: when it malfunctionss, breathing becomes painful or inefficient. For investors, these conditions matter because they drive demand for diagnostics, treatments, hospital stays and medical devices, influence clinical trial results and regulatory decisions, and can affect healthcare costs and company revenues.
intra-abdominal injuriesmedical
Intra-abdominal injuries are damage to the organs, blood vessels or tissues inside the belly — for example the liver, spleen, intestines or major vessels — caused by trauma, disease, or a medical procedure. Think of it like damage under a car’s hood: it can be hidden but serious. For investors, these injuries matter because they drive demand for surgeries, imaging, devices and drugs, affect treatment costs and recovery times, and can influence clinical trial outcomes, insurance payouts and a healthcare company’s revenue and liabilities.
CHICAGO--(BUSINESS WIRE)--
GE HealthCare (Nasdaq: GEHC) today announced a new approximately $35 million expansion to a previous contract with the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS). The expansion is structured as a cost-share between BARDA and GE HealthCare, with BARDA providing the majority of funding. This jointly funded expanded agreement builds on the existing program announced in October 2023 and reflects continued momentum to develop artificial intelligence (AI)-powered ultrasound solutions and new platforms to support trauma assessment and preparedness for mass casualty incidents.
“Responding to a mass casualty incident demands speed, precision and access to care, especially in high-pressure environments like emergency departments, field hospitals, and medical transport,” said Philip Rackliffe, President and CEO, Advanced Visualization Solutions, GE HealthCare. “Our strategic alignment with BARDA enables us to continue to drive ultrasound innovation through advanced AI tools and specialized hardware designed for the front lines of care.”
The expanded clinical scope of the agreement will facilitate development of several new AI-powered tools designed to enhance diagnostic speed and reduce operator dependency, even for non-expert ultrasound users. These new automated capabilities will be designed to support more detailed assessments of lung pathologies, including pleural pathologies, and improve detection of intra-abdominal injuries. In addition, GE HealthCare will create point-of-care ultrasound solutions designed to improve reliability and usability in demanding environments, including field-based care settings.
“GE HealthCare has long been at the forefront of ultrasound innovation in emergency medicine, especially at the point-of-care,” said Karley Yoder, CEO, Comprehensive Care Ultrasound, Advanced Visualization Solutions, GE HealthCare. “This milestone reflects our shared aspiration to equip clinicians with tools that enhance decision-making and help improve patient outcomes in even the most challenging scenarios.”
In addition to further technology development, the expanded program also enables new efforts to engage with clinicians and medical evaluation sites. These activities will help generate clinical evidence, inform ongoing development, and ensure the technology is shaped by real-world feedback. By working directly with experts in emergency medicine, GE HealthCare aims to validate the impact of these innovations and support broader adoption across diverse healthcare environments.
This project is supported in part with federal funds from the U.S. Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA), under contract number 75A50123C00035.
About GE HealthCare Technologies Inc.
GE HealthCare is a leading global healthcare solutions provider of advanced medical technology, pharmaceutical diagnostics, and AI, cloud and software solutions that help clinicians tackle the world’s most complex diseases. Serving patients and providers for 130 years, GE HealthCare is delivering bold innovations designed for the next era of medicine across its Imaging, Advanced Visualization Solutions, Patient Care Solutions, and Pharmaceutical Diagnostics segments to help clinicians deliver more personalized, precise patient care. We are a $20.6 billion business with approximately 54,000 colleagues working to create a world where healthcare has no limits.
